F.X. Eich

404 total citations
13 papers, 228 citations indexed

About

F.X. Eich is a scholar working on Psychiatry and Mental health, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, F.X. Eich has authored 13 papers receiving a total of 228 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Psychiatry and Mental health, 2 papers in Pharmacology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in F.X. Eich's work include Schizophrenia research and treatment (7 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Tryptophan and brain disorders (2 papers). F.X. Eich is often cited by papers focused on Schizophrenia research and treatment (7 papers), Health Systems, Economic Evaluations, Quality of Life (2 papers) and Tryptophan and brain disorders (2 papers). F.X. Eich collaborates with scholars based in Germany, United States and France. F.X. Eich's co-authors include Michael Linden, Dieter Naber, Martin Lambert, Sebastian Härtter, Christoph Hiemke, Melanie Schacht, Benno G. Schimmelmann, Matthias J. Müller, Michael Riedel and H.‐J. Möller and has published in prestigious journals such as European Journal of Pharmacology, Acta Psychiatrica Scandinavica and Journal of Psychiatric Research.

In The Last Decade

F.X. Eich

13 papers receiving 222 citations

Peers

F.X. Eich
Julián Bustin Argentina
Baerbel Allingham United States
Olubanke Olofinjana United Kingdom
Saurabh Kaushik United States
Maria Atkins United Kingdom
F.X. Eich
Citations per year, relative to F.X. Eich F.X. Eich (= 1×) peers Catherine Faget-Agius

Countries citing papers authored by F.X. Eich

Since Specialization
Citations

This map shows the geographic impact of F.X. Eich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F.X. Eich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F.X. Eich more than expected).

Fields of papers citing papers by F.X. Eich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F.X. Eich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F.X. Eich. The network helps show where F.X. Eich may publish in the future.

Co-authorship network of co-authors of F.X. Eich

This figure shows the co-authorship network connecting the top 25 collaborators of F.X. Eich. A scholar is included among the top collaborators of F.X. Eich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F.X. Eich. F.X. Eich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Lambert, Martin, BG Schimmelmann, Dieter Naber, et al.. (2009). Early- and Delayed Antipsychotic Response and Prediction of Outcome in 528 Severely Impaired Patients with Schizophrenia Treated with Amisulpride. Pharmacopsychiatry. 42(6). 277–283. 34 indexed citations
2.
Riedel, Michael, F.X. Eich, & H.‐J. Möller. (2008). A pilot study of the safety and efficacy of amisulpride and risperidone in elderly psychotic patients. European Psychiatry. 24(3). 149–153. 17 indexed citations
3.
Linden, Michael, F.X. Eich, & Lena Pyrkosch. (2007). Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride. International Clinical Psychopharmacology. 22(3). 175–178. 6 indexed citations
4.
Lambert, Martin, Dieter Naber, F.X. Eich, et al.. (2006). Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatrica Scandinavica. 115(2). 106–113. 44 indexed citations
5.
Sachse, J, et al.. (2006). Gender Aspects in the Clinical Treatment of Schizophrenic Inpatients With Amisulpride: A Therapeutic Drug Monitoring Study. Pharmacopsychiatry. 39(2). 41–46. 22 indexed citations
6.
Müller, Matthias J., et al.. (2005). Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia. Journal of Psychiatric Research. 41(8). 673–679. 35 indexed citations
7.
Linden, Michael, Tabea Scheel, & F.X. Eich. (2004). Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study. Human Psychopharmacology Clinical and Experimental. 19(2). 111–119. 14 indexed citations
8.
Herrmann, W.M., et al.. (1993). Pilot Controlled Double-Blind Study of the Hypnotic Effects of Zolpidem in Patients with Chronic ‘Learned’ Insomnia: Psychometric and Polysomnographic Evaluation. Journal of International Medical Research. 21(6). 306–322. 28 indexed citations
9.
LʼHéritier, C., et al.. (1992). PILOT STUDIES ON THE EFFECT OF SL 82.0715 IN PSYCHOTIC SYNDROMES. Clinical Neuropharmacology. 15. 699A–700A. 4 indexed citations
10.
Huwer, Hanno, et al.. (1991). Adenocarcinoma of the Lung: A Contribution on Prognosis after Potentially Curative Resection. The Thoracic and Cardiovascular Surgeon. 39(6). 376–378. 1 indexed citations
11.
Engel, Rolf R., et al.. (1990). Effects of Single Doses of Alpidem, Lorazepam, and Placebo on Memory and Attention in Healthy Young and Elderly Volunteers. Pharmacopsychiatry. 23(S 3). 114–119. 13 indexed citations
12.
Schaffler, K., G. Bianchetti, F.X. Eich, et al.. (1990). CNS-pharmacodynamics and pharmacokinetics of the new non-sedative H1-antihistamine SL8S.0324 vs placebo and dimetinden in volunteers. European Journal of Pharmacology. 183(2). 595–596. 9 indexed citations
13.
Eich, F.X., et al.. (1990). [Nerve conduction velocity following high-dose vincristine in the treatment of small cell bronchial cancer].. PubMed. 44 Suppl 1. 574–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026